|
|
???tair.name??? >
???browser.page.title.author???
|
"belanger b"???jsp.browse.items-by-author.description???
Showing items 6-30 of 35 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2019-01 |
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Hubner, RA;Cubillo, A;Blanc, JF;Melisi, D;Von Hoff, DD;Wang-Gillam, A;Chen, LT;Becker, C;Mamlouk, K;Belanger, B;Yang, Y;de Jong, FA;Siveke, JT |
| 國家衛生研究院 |
2018-11-07 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
|
Chen, LT;Siveke, JT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, AP;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, FS;Mamlouk, K;Belanger, B;de Jong, FA;Hubner, RA |
| 國家衛生研究院 |
2018-10 |
The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)
|
Chen, LT;Macarulla, TM;Belanger, B;Mirakhur, B;de Jong, FA;Siveke, J |
| 國家衛生研究院 |
2018-10 |
Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1
|
Chen, LT;Macarulla, TM;Blanc, J;Mirakhur, B;de Jong, FA;Belanger, B;Bekaii-Saab, T;Siveke, J |
| 國家衛生研究院 |
2018-05 |
A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
|
Wang-Gillam, A;Hubner, R;Mirakhur, B;de Jong, F;Belanger, B;Chen, LT |
| 國家衛生研究院 |
2018-02 |
Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) +/- 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1.
|
Wang-Gillam, A;Hubner, R;Mirakhur, B;de Jong, FA;Belanger, B;Chen, LT |
| 國家衛生研究院 |
2018-02 |
Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pan
|
Siveke, JT;Hubner, R;Macarulla, TM;Wang-Gillam, A;Dean, AP;Blanc, JF;Cunningham, D;Mirakhur, B;Belanger, B;de Jong, FA;Chen, LT |
| 國家衛生研究院 |
2018-02 |
Dose modifications of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy
|
Wang-Gillam, A;Hubner, R;Mirakhur, B;de Jong, FA;Belanger, B;Chen, LT |
| 國家衛生研究院 |
2017-11 |
CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) � 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Wang-Gillam, A;Shan, YS;Mercade, TM;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, J;Belanger, B;de Jong, F;Mamlouk, K;von Hoff, D |
| 國家衛生研究院 |
2017-09 |
Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alon
|
Hubner, RA;Chen, LT;Li, CP;Bodoky, G;Dean, A;Lee, KH;Cunningham, D;Siveke, JT;Braiteh, FS;de Jong, FA;Belanger, B;Walls, R;Mody, PD;von Hoff, DD;Wang-Gillam, A |
| 國家衛生研究院 |
2017-05 |
The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM
|
Wang-Gillam, A;Chen, LT;Li, CP;Bodoky, G;Dean, A;Lee, KH;Cunningham, D;Hubner, R;Braiteh, FS;Pipas, JM;Belanger, B;de Jong, FA;Mody, PD;Von Hoff, DD;Siveke, JT |
| 國家衛生研究院 |
2017-02 |
Nanoliposomal irinotecan in the clinical practice guideline for metastatic pancreatic cancer: Applicability to clinical situations
|
Wang-Gillam, A;Von Hoff, D;Siveke, J;Hubner, R;Belanger, B;Pipas, JM;Chen, LT |
| 國家衛生研究院 |
2017-02 |
Efficacy and safety of liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPO
|
Chen, LT;Wang-Gillam, A;Yanshen, S;Macarulla, T;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Pipas, JM;Belanger, B;de Jong, F;Mamlouk, K;Von Hoff, DD |
| 國家衛生研究院 |
2017-02 |
Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-FU/LV
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Lee, KH;Cunningham, D;Hubner, R;Siveke, JT;Braiteh, FS;Pipas, JM;Belanger, B;de Jong, F;Mody, PD;Chen, LT;Von Hoff, DD |
| 國家衛生研究院 |
2016-12 |
Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study
|
Chen, LT;Li, CP;Chiu, CF;Shan, YS;Park, JO;Chen, JS;Kim, JS;Rau, KM;de Jong, F;Pipas, M;Belanger, B;Wang, E;Lee, KH;Bang, YJ |
| 國家衛生研究院 |
2016-12 |
Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1
|
Hubner, R;Cubillo, A;Blanc, JF;Melisi, D;von Hoff, DD;Wang-Gillam, A;Chen, LT;Becker, C;Mamlouk, K;Belanger, B;Yang, Y;de Jong, F;Siveke, JT |
| 國家衛生研究院 |
2016-10 |
Effects of nanoliposomal irinotecan (nal-IRI;MM-398) +/- 5-Fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-b
|
Siveke, JT;Cubillo, A;Blanc, JF;Melisi, D;Von Hoff, DD;Wang-Gillam, A;Chen, LT;Becker, C;Mamlouk, K;Belanger, B;Yang, Y;de Jong, F;Hubner, R |
| 國家衛生研究院 |
2016-10 |
Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Braiteh, F;Belanger, B;Bayever, E;de Jong, F;von Hoff, DD;Siveke, JT |
| 國家衛生研究院 |
2016-10 |
Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther
|
Hubner, RA;Chen, LT;Siveke, JT;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, F;Mamlouk, K;Belanger, B;de Jong, F;von Hoff, DD;Wang-Gillam, A |
| 國家衛生研究院 |
2016-06 |
Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine
|
Hubner, R;Cubillo, A;Blanc, JF;Melisi, D;Von Hoff, D;Wang-Gillam, A;Chen, LT;Becker, C;Mamlouk, K;Belanger, B;Yang, Y;De Jong, F;Siveke, J |
| 國家衛生研究院 |
2016-06 |
Safety across subgroups in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Siveke, J;Wang-Gillam, A;Hubner, R;Pant, S;Dragovich, T;Chung, V;Chang, D;Ross, P;Cooray, P;Tebbutt, N;Franke, F;Belanger, B;Dhindsa, N;de Jong, F;Mamlouk, K;Von Hoff, D |
| 國家衛生研究院 |
2016-05-14 |
Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply
|
Chen, LT;Wang-Gillam, A;Von Hoff, DD;Bayever, E;Belanger, B |
| 國家衛生研究院 |
2016-05 |
Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E;Von Hoff, DD;Chen, LT |
| 國家衛生研究院 |
2016-05 |
Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1: A randomized phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy
|
Chen, LT;Siveke, JT;Wang-Gillam, A;Hubner, R;Pant, S;Dragovich, T;Chung, VM;Chang, DZ;Ross, PJ;Cooray, P;Tebbutt, NC;Franke, FA;Belanger, B;Dhindsa, N;de Jong, F;Mamlouk, K;Von Hoff, DD |
| 國家衛生研究院 |
2016-02 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, RA;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, F;Moyo, V;Belanger, B;Dhindsa, N;Bayever, E;Von Hoff, DD;Chen, LT;the NAPOLI-1 Study Group. |
Showing items 6-30 of 35 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
|
